Signe Ridderberg

Title: Signe Ridderberg: Innovator in Insulin Delivery Systems

Introduction

Signe Ridderberg is a prominent inventor based in Lyngby, Denmark. She has made significant contributions to the field of diabetes management through her innovative work on insulin derivatives. Her research focuses on developing advanced solutions for insulin delivery that respond to glucose levels in the body.

Latest Patents

Signe Ridderberg holds a patent for her invention titled "Glucose dependent release of insulin from glucose sensing insulin derivatives." This patent describes insulin derivatives that incorporate a built-in glucose sensor. These derivatives are capable of releasing insulin from a depot based on the glucose concentration in the surrounding medium, such as tissue. The rate of insulin release increases with higher glucose concentrations and decreases when glucose levels drop. This innovation has the potential to improve diabetes treatment by providing more precise insulin delivery.

Career Highlights

Signe Ridderberg is associated with Novo Nordisk A/S, a leading global healthcare company specializing in diabetes care. Her work at Novo Nordisk has positioned her as a key player in the development of cutting-edge diabetes management solutions. With her expertise, she has contributed to advancements that enhance the quality of life for individuals living with diabetes.

Collaborations

Signe has collaborated with notable colleagues, including Thomas Hoeg-Jensen and Svend Havelund. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas in the field of diabetes research.

Conclusion

Signe Ridderberg's contributions to insulin delivery systems represent a significant advancement in diabetes management. Her innovative approach to developing glucose-responsive insulin derivatives showcases her commitment to improving patient care. Through her work, she continues to make a lasting impact in the field of medical science.